← All trials
NCT04797013
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2021
- Primary completion
- Jul 31, 2022
- Completion date
- Oct 31, 2023
- First posted
- Mar 15, 2021
- Last posted
- Jul 28, 2021
- Enrollment
- 1430
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversityReponsible party - principal investigator
- Guangzhou Recomgen Biotech Co., Ltd.Collaborator
- Capital Medical UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.